Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Sep 2, 2014
8:30 AM ET
Webcast IR Thematic Call on Alirocumab
Sep 3, 2014
4:05 PM ET
Webcast Baird 2014 Healthcare Conference
Sep 4, 2014
10:00 AM ET
Webcast Citi's 9th Annual Biotech Conference
Sep 8, 2014
8:45 AM ET
Webcast Morgan Stanley Global Healthcare Conference


View all releases Recent Press Releases

Aug 25, 2014 Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Aug 19, 2014 Regeneron Announces Upcoming 2014 Investor Conference Presentations
Aug 11, 2014 EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Aug 5, 2014 Regeneron Reports Second Quarter 2014 Financial and Operating Results
Jul 30, 2014 Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014 Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Jul 29, 2014 EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
Jul 18, 2014 Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Jul 18, 2014 Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis


Close
Form content here please :)